Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.
Review published in Current oncology (Toronto, Ont.) (2018)
Abstract
Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show variation in their risk for recurrent vte and adverse bleeding events. Accordingly, a committee of 10 Canadian clinical experts developed the consensus risk- stratification treatment algorithm presented here to provide guidance on tailoring anticoagulant treatment choices for the acute and extended treatment of symptomatic and incidental vte, to prevent recurrent vte, and to minimize the bleeding risk in patients with cancer. During a 1-day live meeting, a systematic review of the literature was performed, and a draft treatment algorithm was developed. The treatment algorithm was refined through the use of a Web-based platform and a series of online teleconferences. Clinicians using this treatment algorithm should consider the bleeding risk, the type of cancer, and the potential for drug-drug interactions in addition to informed patient preference in determining the most appropriate treatment for patients with cancer-associated thrombosis. Anticoagulant therapy should be regularly reassessed as the patient's cancer status and management change over time.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show...
Warum dies für die Hirudotherapie relevant ist
Diese Konsenserklärung und systematische Übersicht entwickelte einen risikostratifizierten Behandlungsalgorithmus zur Steuerung der Antikoagulanzientherapie bei venöser Thromboembolie (VTE) bei Krebspatienten unter Berücksichtigung von Blutungsrisiko, Krebsart und Arzneimittelwechselwirkungen. Der Abstract behandelt das Management krebsassoziierter Thrombose unter Verwendung konventioneller systemischer Antikoagulanzien. Für die American Society of Hirudotherapy ist das Thema der Antikoagulation bei thrombotischen Erkrankungen konzeptionell benachbart, der Abstract enthält jedoch keine Erwähnung von Blutegeln, Hirudotherapie, dem Blutegel-Sekretom oder einer lokalisierten Antikoagulationstherapie. Die Relevanz für die Hirudotherapie ist rein indirekt und liefert Hintergrundinformationen zum Standard-Antikoagulationsmanagement ohne jegliche blutegelbezogenen Inhalte.
Zitation
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.
Carrier et al. · Current oncology (Toronto, Ont.), 2018
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026